Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 70 от 240

Набира участници

A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence

Infertility Male Factor Infertility

This research is being done to determine if producing sperm after an ultrashort period of abstinence (1 hour of abstinence) will be effective in improving the rates of embryos with normal chromosomes (structures that carry genetic information) during in vitro fertilization (IVF) treatment. The investigators hypothesize that a shorter period of abstinence is effective at improving rates of normal chromosomes among embryos.

Начало: 27.07.2025 Край: 01.06.2027 Възраст: 18–42 г.

United States UConn Health NCT07062237

Набира участници

A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)

Kidney Failure Frailty Kidney Disease, Chronic

The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are: * To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible. * To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements. * To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks.

Начало: 25.07.2025 Край: 01.10.2026 Възраст: от 18 г.

Canada Seven Oaks Hospital Chronic Disease Innovation Centre NCT06343727

Набира участници Фаза 2/3

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

Pericarditis Pericarditis Acute Recurrent Pericarditis

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

Начало: 25.07.2025 Край: 31.12.2029 Възраст: 18–80 г.

Canada, France, Greece +6 Kiniksa Pharmaceuticals International, plc NCT07010159

Набира участници Фаза 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Atherosclerotic Cardiovascular Disease Overweight Obesity

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Начало: 25.07.2025 Край: 29.09.2030 Възраст: 45–99 г. Лечение

Argentina, Australia, Austria +32 Amgen NCT07037433

Набира участници Фаза 1

A Study of LY4088044 in Healthy Participants

Healthy

The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.

Начало: 24.07.2025 Край: 01.07.2027 Възраст: 18–65 г. Фундаментална наука

New Zealand, Singapore, United States Eli Lilly and Company NCT07090785

Набира участници

Left Bundle Branch Area Pacing (LBBAP) PMCF Study

Bradycardia Right Ventricular Pacing Heart Failure Atrial Fibrillation (AF) +3

The objective of this study is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients implanted with the Tendril STS 2088TC or UltiPace LPA1231 lead through 6 months post-implant.

Начало: 24.07.2025 Край: 30.04.2027 Възраст: от 18 г.

Brazil, France, Germany +4 Abbott Medical Devices NCT07217392

Набира участници Фаза 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Non-Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung (NSCLC)

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.

Начало: 23.07.2025 Край: 01.03.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Austria +27 Pfizer NCT06758401

Набира участници Фаза 1

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

The primary objective of this study is to evaluate the safety and tolerability of a single dose of INS1201 via IT administration in ambulatory male participants with DMD.

Начало: 22.07.2025 Край: 31.03.2028 Възраст: 2–4 г.

United States Insmed Gene Therapy LLC NCT06817382

Набира участници Фаза 2

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

AML

The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell transplant.

Начало: 22.07.2025 Край: 31.01.2030 Възраст: 65–75 г.

United States M.D. Anderson Cancer Center NCT06973668

Набира участници Фаза 2

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Neoadjuvant Treatment Thyroid Cancer

To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.

Начало: 22.07.2025 Край: 01.10.2030 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT06959511

Набира участници

Discovery and Validation of Periodontitis Biomarkers

Periodontitis Biomarker in Early Diagnosis Saliva

Periodontitis is a major public health issue in China: it is responsible for loss of masticatory function in 60 million older adults, and 400-500 million adults are on the same disease trajectory. In addition, gingivitis and early-stage periodontitis are highly prevalent in all age groups. The Lancet 2021 burden of disease study provides worrying projections for China's oral health, with a 47.8% increase in advanced-stage periodontitis and a 217% increase in edentulism by the year 2050. The numbers are not manageable by the Chinese health system unless a series of coordinated actions are implemented: i) health education promoting oral hygiene in school and the workplace; ii) effective AI-based self-detection strategies and accurate identification of high-risk subjects; iii) efficient treatment modalities; and iv) reorganization of the health system. We have developed, patented, and validated a self-detection AI-based screening test for the general population through an app. It is based on a few validated questions and the performance of a lateral flow immunoassay to detect activated matrix metalloproteinase 8 (aMMP8). The algorithm enables accurate self-detection of severe periodontitis. The system, however, cannot identify subjects without clinically evident periodontitis (subjects who present with superficial inflammation consistent with gingivitis and incipient periodontitis) who will develop the disease, which, therefore, should be the target of early interventions. This limitation is due to insufficient knowledge of the process that turns superficial inflammation (gingivitis) into periodontitis. This limitation is apparent in the recently published NIH-sponsored American diagnostic trial results to detect periodontitis onset biomarkers (and progression). In their study, Teles et al. (2024) show that almost 24% of gingivitis subjects progress to periodontitis over a 12-month period but failed to identify salivary or serum biomarkers. Similarly, our recently completed study (Li et al. in preparation) did not identify highly accurate biomarkers for disease onset and progression. Importantly, the American and our study have tested putative biomarkers identified based on the current crude knowledge of the disease process. Gaps in fundamental knowledge are now apparent and limit our ability to detect periodontitis early. In addition, the current crude differential diagnosis based on clinical examination with a periodontal probe with millimeter markings cannot accurately differentiate gingivitis from early-stage periodontitis, complicating the ground truth definition (gold standard). In the current study, we propose implementing a multi-omics approach to test the ability to discriminate a mixed population of clinically undifferentiable gingivitis and stage I periodontitis into two or more clusters. In this biomarker discovery phase, we plan to use multiple state-of-the-art methods: i) laser scanning microdissection proteomics of tissue biopsies, ii) conventional salivary proteomics, iii) tissue biopsy transcriptomics, and iv) shotgun microbiome analysis. The methods will be applied in an agnostic approach to test the following hypotheses: 1. It is possible to identify two or more clusters of subjects from a mixed population of gingivitis and stage I periodontitis subjects. 2. The clusters differ based on host-derived biomarkers and/or microbiome factors and the risk of progression to periodontitis. 3. The biomarker pathways and microbial virulence factors among subjects identified according to the different approaches used to explore disease biology are generally consistent. 4. It is possible to identify a limited set of biomarkers that can be used to predict periodontitis onset and thus target early interventions for this high-risk population.

Начало: 21.07.2025 Край: 31.10.2027 Възраст: 18–40 г.

China Shanghai Ninth People's Hospital Affiliated to Shanghai NCT07293481

Набира участници Фаза 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.

Начало: 21.07.2025 Край: 14.07.2033 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +21 Merck Sharp & Dohme LLC NCT07060807

Набира участници

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

Prostate Cancer Prostate Cancer (Diagnosis) Prostate Cancer (Post Prostatectomy) Prostate Cancer Patients Treated by Radiotherapy +2

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Начало: 21.07.2025 Край: 21.07.2026 Възраст: от 19 г.

Algeria Société Algérienne de Formation et Recherche en Oncolog NCT07484971

Набира участници

Young Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke

Stroke Patients Stroke Stroke; Sequelae Young Adults

The Investigators are running a small, early-phase research study across several hospitals in Melbourne, Australia. The study will involve up to 100 young adults between the ages of 18 and 55 who have had a stroke. The goal is to test how practical it is to carry out a detailed health assessment process-called "deep phenotyping"-with this group. This process involves collecting a wide range of information and samples from stroke survivors to better understand each participant's condition. The Investigators will look at how well this approach works in practice, including how easy it is to use, whether it's done consistently, and how acceptable it is to participants. At the same time, the Investigators will also explore how different factors-such as biological markers (biomarkers), age, sex, type of stroke, lifestyle, and environment-might be related to stroke recovery. This pilot study will prepare for larger studies in the future.

Начало: 19.07.2025 Край: 01.12.2027 Възраст: 18–55 г.

Australia The Florey Institute of Neuroscience and Mental Health NCT07019493

Набира участници Фаза 3

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Bipolar Disorder Type I With Mania

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

Начало: 18.07.2025 Край: 13.06.2028 Възраст: 18–65 г. Лечение

Argentina, Australia, Bulgaria +17 Bristol-Myers Squibb NCT06929273

Набира участници Фаза 1/2

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Metastatic Colorectal Cancer

This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's immune system fight cancer in combination with another new treatment (BNT327, which is an immune checkpoint inhibitor) and chemotherapy in participants with metastatic colorectal cancer (mCRC). This study will enroll participants with microsatellite stable or mismatch repair proficient (MSS/pMMR) mCRC who did not respond well to their first schema of chemotherapy. In one part of the study (i.e., Part B) mCRC participants will be enrolled, who have not received any systemic therapy before for their cancer.

Начало: 18.07.2025 Край: 01.05.2031 Възраст: от 18 г.

Germany, Japan, Spain +2 BioNTech SE NCT07079631

Набира участници Фаза 2

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.

Начало: 17.07.2025 Край: 06.09.2028 Възраст: от 18 г.

Canada, China, Georgia +8 AstraZeneca NCT07069712

Набира участници

Positive Processes and Transition to Health - Single-Session (PATH-SS)

PTSD Depression

The goal of this clinical trial is to test a brief, new psychotherapy (called Positive Processes and Transition to Health - Single Session, or PATH-SS) that aims to provide relief for people who are suffering after experiencing a sexual assault. This research will explore whether this new psychotherapy reduces sexual assault related distress, including posttraumatic stress and depression symptoms. The main questions it aims to answer are: Does PATH-SS leads to improvements in PTSD and depression symptoms (pre- to post- and 1-month follow-up)? Do participants perceive PATH-SS to be acceptable, helpful, and do they complete/adhere to treatment? Participants will complete a pre-treatment/baseline assessment to confirm eligibility, and those who are eligible will receive the single-session intervention and will complete a post-treatment and a 1-month follow-up assessment of stressor-related symptoms.

Начало: 17.07.2025 Край: 31.05.2027 Възраст: 18–65 г.

United States Case Western Reserve University NCT06900712

Набира участници Фаза 3

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Premature Ovarian Insufficiency

Background: Premature ovarian insufficiency (POI) is a condition in which women under the age of 40 years have absent or irregular menstrual cycles. POI can cause infertility, signs of menopause, osteoporosis, and other symptoms. Hormone replacement therapy (HRT) is a treatment that gives women extra hormones, such as estrogen and progesterone. HRT works well in adult women. Researchers want to find the most effective doses and regimens for adolescents. Objective: To monitor the effects of HRT on adolescents with POI. Eligibility: Female adolescents aged 11 to 19 years diagnosed with POI. Healthy volunteers are also needed. Design: All participants will have clinic visits every 6 months for 2 years. Each visit may last 2 days. Each visit may include: Blood and urine tests. A test of their heart function. A test to measure the stiffness of their blood vessels. Participants will lie flat with a blood pressure cuff on a leg and a meter on the neck while the cuff inflates. A test of their grip strength. Participants will squeeze a handheld device as hard as they can. Two scans to measure bone density. For one, participants will lie on a table while a scanner passes along their body. For the other, participants will sit in a chair and insert their forearm, then their lower leg, into a scanner. A test to measure skin pigmentation. Participants skin will be touched lightly with a device. An optional visual exam of the vagina. Some vaginal fluid may also be collected with a cotton swab/cytobrush. Participants with POI will receive HRT. They will be given estrogen patches and progesterone pills.

Начало: 17.07.2025 Край: 31.12.2031 Възраст: 11–19 г.

United States Eunice Kennedy Shriver National Institute of Child Heal NCT06851754

Набира участници Фаза 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Alzheimer Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Начало: 16.07.2025 Край: 13.11.2028 Възраст: 55–90 г.

Argentina, Chile, Czechia +11 Bristol-Myers Squibb NCT07011745

1 … 68 69 70 71 72 … 240